Drug intelligence / Profile preview

IDM-2

Development stage: Discontinued
Lead developer: Takeda
Modality: Cell Therapies
Administration: Intravesical

Overview

IDM-2 is an autologous cell-based immunotherapy consisting of Monocyte-derived Activated Killer (MAK) cells. The therapy is produced by harvesting monocytes from a patient's peripheral blood via leukapheresis, which are then differentiated into macrophages and activated ex vivo using recombinant interferon-gamma. These activated macrophages are designed to recognize and destroy tumor cells through direct cytotoxicity and phagocytosis. IDM-2 was developed for the treatment of superficial bladder cancer, administered via intravesical instillation following transurethral resection of the tumor to prevent recurrence. The program was originally developed by IDM Pharma (formerly Immuno-Designed Molecules).

Brand names: Uromac
Other names: Monocyte-derived Activated Killer cellsMAK cellsactivated macrophages

Beyond the preview

Go deeper on IDM-2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IDM-2.

Explore the full profile